Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Telpefilgrastim is a recombinant human granulocyte colony-stimulating factor (G-CSF) analog, developed as a biosimilar to filgrastim. Like other G-CSF agents, it stimulates the proliferation and differentiation of neutrophil precursors, leading to increased production of neutrophils in the blood. This mechanism helps reduce the incidence and duration of neutropenia (low white blood cell count) in patients undergoing myelosuppressive chemotherapy or bone marrow transplantation, and may also be used for mobilizing hematopoietic progenitor cells for collection by leukapheresis. Telpefilgrastim is designed to closely mimic endogenous G-CSF but is produced using recombinant DNA technology.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on telpefilgrastim.